Phase II study with conventional radiotherapy (RT) + cetuximab in patients with advanced larynx cancer who responded to induction chemotherapy (IC): An organ preservation TTCC study

MLA

Joaquina Martinez Galan, et al. “Phase II Study with Conventional Radiotherapy (RT) + Cetuximab in Patients with Advanced Larynx Cancer Who Responded to Induction Chemotherapy (IC): An Organ Preservation TTCC Study.” Journal of Clinical Oncology, vol. 33, May 2015, p. 6037. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........b3bab0521f2843ace4dcca67fca0826c&authtype=sso&custid=ns315887.

APA

Joaquina Martinez Galan, M. Pastor, Javier Martínez Trufero, Silvia Vazquez, Jordi Rubió, Elvira del Barco, Angeles Rodriguez Jaraiz, Esther Casado, Ricard Mesia, Julio Jose Lambea Sorrosal, José Ángel García Sáenz, Miren Taberna, Juan Jesús Cruz, Juan J. Grau, Beatriz Cirauqui, Alicia Lozano, J. R. Mel, Belen Gonzalez, & Manel Manos Pujol. (2015). Phase II study with conventional radiotherapy (RT) + cetuximab in patients with advanced larynx cancer who responded to induction chemotherapy (IC): An organ preservation TTCC study. Journal of Clinical Oncology, 33, 6037.

Chicago

Joaquina Martinez Galan, M. Pastor, Javier Martínez Trufero, Silvia Vazquez, Jordi Rubió, Elvira del Barco, Angeles Rodriguez Jaraiz, et al. 2015. “Phase II Study with Conventional Radiotherapy (RT) + Cetuximab in Patients with Advanced Larynx Cancer Who Responded to Induction Chemotherapy (IC): An Organ Preservation TTCC Study.” Journal of Clinical Oncology 33 (May): 6037. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........b3bab0521f2843ace4dcca67fca0826c&authtype=sso&custid=ns315887.